Holen Sie sich die Stockscreener-App
5.01
2.24%
0.11
Schlusskurs vom Vortag:
$4.90
Offen:
$4.94
24-Stunden-Volumen:
26,580
Relative Volume:
0.13
Marktkapitalisierung:
$40.97M
Einnahmen:
$120.77M
Nettoeinkommen (Verlust:
$32.69M
KGV:
1.7189
EPS:
2.9146
Netto-Cashflow:
$-50.94M
1W Leistung:
-4.93%
1M Leistung:
+0.40%
6M Leistung:
-65.42%
1J Leistung:
-34.08%
1-Tages-Spanne:
$4.8005
$5.1117
1-Wochen-Bereich:
$4.8005
$5.30
52-Wochen-Spanne:
$3.92
$19.14
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Firmenname
Atara Biotherapeutics Inc
Sektor
Branche
Telefon
805-623-4211
Adresse
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Compare ATRA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
5.01 | 40.07M | 120.77M | 32.69M | -50.94M | 2.9146 |
VRTX
Vertex Pharmaceuticals Inc
|
430.29 | 110.67B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
751.57 | 80.98B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
780.25 | 49.00B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
305.54 | 41.87B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
300.80 | 33.28B | 5.36B | 287.73M | 924.18M | 2.5229 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-13 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-11-09 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-11-09 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-07-20 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-07-13 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-07-13 | Herabstufung | Stifel | Buy → Hold |
| 2022-05-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-05-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-12-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-30 | Eingeleitet | Evercore ISI | Outperform |
| 2020-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-23 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-11-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-09-27 | Herabstufung | Goldman | Neutral → Sell |
| 2019-09-16 | Herabstufung | Jefferies | Buy → Hold |
| 2019-06-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2019-05-30 | Eingeleitet | ROTH Capital | Buy |
| 2019-05-23 | Eingeleitet | Stifel | Buy |
| 2019-01-23 | Eingeleitet | Mizuho | Buy |
| 2018-04-10 | Eingeleitet | JP Morgan | Overweight |
| 2018-03-16 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-05 | Bestätigt | Jefferies | Buy |
| 2018-02-28 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-01-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
Alle ansehen
Atara Biotherapeutics Inc Aktie (ATRA) Neueste Nachrichten
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, I - GuruFocus
Atara Biotherapeutics (NASDAQ: ATRA) sets 2026 virtual meeting and equity plan vote - Stock Titan
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Barchart.com
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire Inc.
Lost Money on Atara Biotherapeutics, Inc. (ATRA)? Join - GlobeNewswire
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionATRA - TMX Newsfile
Bronstein, Gewirtz & Grossman LLC Urges Atara - GlobeNewswire
2026-04-23 | ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! | NDAQ:ATRA | Press Release - Stockhouse
ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to ... - Black Hills Pioneer
ATRA INVESTOR ALERT: Contact Kirby McInerney LLP About Securities Class Action Lawsuit On Behalf of Atara Biotherapeutics, Inc. Investors - ACCESS Newswire
ATRA DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 - The Malaysian Reserve
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
DEADLINE ALERT for LU, ATRA, and COTY: The Law Offices of - GlobeNewswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. LawsuitATRA - Morningstar
ATRA DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Atara Biothera - GuruFocus
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money H - GuruFocus
Robbins LLP Urges ATRA Stockholders to Contact the Firm for - GlobeNewswire
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
ATRA Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Atara Biotherapeutics, Inc. Securities Lawsuit — The Gross Law Firm - Morningstar
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
ATRA Shareholder Alert: Investors With Losses May Seek to Lead t - GuruFocus
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Atara Biotherapeutics, Inc. Investors - GlobeNewswire
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionATRA - ACCESS Newswire
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit - The Killeen Daily Herald
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure ... - Black Hills Pioneer
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Atara - GlobeNewswire
REMINDER: Atara Biotherapeutics, Inc. Investors With Significant - The National Law Review
REMINDER: Atara Biotherapeutics, Inc. Investors With Significant Losses Must Act By May 22, 2026 – Contact Kirby McInerney LLP - Business Wire
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionATRA - TMX Newsfile
Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, Inc. Investors They Have Until ... - Eagle-Tribune
Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, - GlobeNewswire
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ATRA Shareholder Alert: May 22, 2026 Lead Plaintiff - GlobeNewswire
ATRA Stockholders Have RightsIf You Lost Money Investing in A - GuruFocus
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionATRA - TMX Newsfile
Atara Biotherapeutics Faces Securities Lawsuit After FDA Setbacks and Sharp Stock Declines Tied to Tabelecleucel - TipRanks
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ATRA INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds - GuruFocus
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain OfficersATRA - ChartMill
ATRA INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 - ChartMill
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
2026-04-16 | ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:ATRA | Press Release - Stockhouse
ROSEN, A LEADING LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel ... - Caledonian Record
ROSEN, A LEADING LAW FIRM, Encourages Atara - GlobeNewswire
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Finanzdaten der Atara Biotherapeutics Inc-Aktie (ATRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.01%
0.61%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):